Articles tagged "Induction therapy"

2016 American Transplant Congress
Induction Therapy in Low Risk African American Kidney Transplant Recipients: Donor Factors.
F. Al Ammary,¹ S. Bae,¹ A. Massie,¹ N. Dagher,¹ E. King,¹ A. Wiseman,² D. Segev.¹
¹JHU, Baltimore; ²CU, Denver.
African Americans (AA) are at a higher risk of acute rejection and graft loss compared to non-AA kidney transplant (KT) recipients. Guidelines specify induction choices…
2016 American Transplant Congress
Induction Immunosuppression and Post-Transplant Outcomes in Kidney Recipients with Hepatitis C Virus.
S. Bae, C. Durand, L. Kucirka, A. Massie, D. Segev.
Johns Hopkins, Baltimore, MD.
Kidney transplantation is a well-established treatment option for ESRD patients with Hepatitis C virus (HCV). However, the optimal induction regimen for this population is uncertain,…
2016 American Transplant Congress
Evaluation of Dose Dependent Rabbit Anti-Thymocyte Globulin Induction in Risk-Stratified Kidney Transplant Recipients.
I. Gutman, M. Misel, D. McKay, A. Hemming, J. Kerr, K. Mekeel.
UC San Diego Health System, San Diego, CA.
Background: Rabbit anti-thymocyte globulin (rATG) is a depleting polyclonal antibody often used for induction following kidney transplantation to help prevent acute rejection. The optimal dosage…
2016 American Transplant Congress
A Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin (rATG) 3mg/Kg vs. 6mg/Kg in Kidney Transplant Patients Under Minimization Maintenance Immunosuppressive Regimen.
T. Sandes-Freitas, J. Junqueira Junior, M. Oliveira, C. Girão, R. Esmeraldo.
Hospital Geral de Fortaleza, Fortaleza, Brazil.
Background: rATG dosed from 4.5 to 7.5mg/kg has been the standard of care in most transplant centers. Recent studies have demonstrated similar efficacy with doses…
2016 American Transplant Congress
Tailored Rabbit Anti-Thymocyte Globulin Induction (rATG) Dosing for Kidney Transplantation.
N. Singh,^1,2 A. Rossi,¹ M. Savic,¹ R. Rubocki,¹ M. Parker,¹ J. Vella.¹
¹MMC, Portland, ME; ²MGMC, Augusta, ME.
Purpose: Although rATG is the most commonly used induction immunotherapy for kidney transplantation (KT), optimal dosing remains unknown. In order to minimize adverse effects and…
2016 American Transplant Congress
Alemtuzumab Induction Therapy in Elderly Kidney Transplant Recipients.
I. Yakubu,¹ B. Masters,¹ B. Ravichandran,¹ T. Sparkes,¹ M. Moss,¹ F. Rasetto,¹ S. Jonchhe,¹ B. Thomas,² N. Costa,² D. Leeser,² S. Bartlett,² A. Haririan.²
¹Pharmacy, University of Maryland Medical Center, Baltimore; ²University of Maryland Medical Center, Baltimore.
Background: In descriptive studies, alemtuzumab has been associated with an escalating risk of death and graft loss in elderly (≥65 years) kidney transplant recipients. However,…
2016 American Transplant Congress
Time Trends of Induction Agent Use in Older and Younger Kidney Transplantation Recipients.
Q. Huang, X. Luo, M. McAdams-DeMarco, D. Segev.
Johns Hopkins University, Baltimore, MD.
Older adults are increasingly gaining access to kidney transplantation (KT) yet the use of induction agents in this population is unclear. The goal of this…
2016 American Transplant Congress
Tolerogenic Interactions Between Host CD8⁺Myeloid Dendritic Cells and Natural Killer T Cells Are Required for Acceptance of Combined Organ and Bone Marrow Transplants After TLI Conditioning.
D. Hongo Apum,¹ X. Zhang,² E. Engleman,² S. Strober.¹
¹Medicine - Division of Immunology & Rheumatology, Stanford University, Stanford, CA; ²Medicine - Department of Pathology, Stanford University, Stanford, CA.
Combined transplantation of solid organs and bone marrow or hematopoietic progenitor cells has resulted in successful achievement of tolerance in both laboratory animals and in…
2016 American Transplant Congress
After Alemtuzumab Induction, Tac+MMF Is Superior to CsA+MMF in Pediatric Kidney Transplantation.
M. Kaabak,¹ N. Babenko,¹ A. Zokoyev,¹ R. Shapiro.²
¹Boris Petrovsky SCS, Moscow, Russian Federation; ²Mount Sinai Hospital, New York, NY.
Introduction: Recipient parenchymal lymphatic cells are crucial for direct and indirect pathways of allorecognition. We proposed that administering alemtuzumab several weeks pretransplantation could eradicate peripheral…
2016 American Transplant Congress
A Prospective Randomized, Comparative Trial of High-Dose Mizoribine versus Mycophenolate Mofetil in Combination with Tacrolimus and Basiliximab for Living Donor Renal Transplantation: A Multi-Center Trial.
H. Ishida,¹ K. Tanabe,¹ S. Takahara,² N. Amada,³ K. Takahashi,⁴ H. Toma.⁵
¹Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan; ²Advanced Technology for Transplantation, Osaka University, Osaka, Japan; ³Surgery, JCHO Sendai Hospital, Sendai, Japan; ⁴Niigata Organ Transplant Foundation, Niigata, Japan; ⁵Urology, Toda Chuo Hospital, Toda, Saitama, Japan.
PURPOSE: To compare the clinical outcomes of mizoribine (MZR; 12 mg/kg/day) and mycophenolate mofetil (MMF; 2000 mg/day) in combination with tacrolimus (FK), basiliximab (SIM), and…